US 11,896,577 B2
Short-acting psychoactive compounds of the MDMA class
Denton W. Hoyer, West Haven, CT (US); Robert F. Roscow, Longmont, CO (US); Rong Ling, Edmonton (CA); and Chuanjun Gao, Edmonton (CA)
Assigned to Mydecine Innovations Group Inc., Denver, CO (US)
Filed by Mydecine Innovations Group Inc., Denver, CO (US)
Filed on Jun. 13, 2023, as Appl. No. 18/209,334.
Application 18/209,334 is a continuation in part of application No. PCT/US2022/037193, filed on Jul. 14, 2022.
Claims priority of provisional application 63/322,806, filed on Mar. 23, 2022.
Claims priority of provisional application 63/221,597, filed on Jul. 14, 2021.
Prior Publication US 2023/0321034 A1, Oct. 12, 2023
Int. Cl. A61K 31/39 (2006.01); A61K 31/381 (2006.01); A61K 45/06 (2006.01)
CPC A61K 31/39 (2013.01) [A61K 31/381 (2013.01); A61K 45/06 (2013.01)] 6 Claims
 
1. A MDMA analog compound according to Formula (V) comprising:
wherein:

OG Complex Work Unit Chemistry
X1 is S;
X2 is O;
R1 is NR2R3;
R2 is H or CH3;
R3 is CH3;
or a pharmaceutically acceptable salt thereof.